This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio
by Zacks Equity Research
Solventum buys Acera Surgical for $725M upfront to enter tissue matrices, expanding MedSurg and wound care.
MDPositive Net Change BDSXPositive Net Change BTSGNegative Net Change SOLVNegative Net Change
medical medical-devices
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
by Zacks Equity Research
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
BSXPositive Net Change ANGONo Net Change ISRGNegative Net Change MEDPPositive Net Change
medical medical-devices
HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling?
by Debanjana Dey
Hims & Hers and Teladoc Health are expanding virtual care in different ways, but which telehealth platform looks more compelling right now? Let's dive in.
TDOCPositive Net Change HIMSNegative Net Change
medical medical-devices
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
XFORPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Midland States Bancorp (MSBI) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
MSBINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?
by Moumi Mondal
BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.
ABTPositive Net Change BSXPositive Net Change EWPositive Net Change
medical medical-devices
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?
by Zacks Equity Research
DGX banks on acquisitions, advanced diagnostics and cost discipline, even as debt levels and macro pressures pose risks.
DGXPositive Net Change ILMNNegative Net Change PODDPositive Net Change BTSGNegative Net Change
medical medical-devices
Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside?
by Indrajit Bandyopadhyay
Intuitive Surgical's robotics-first model, recurring revenue base, and margin leverage differentiate it from Stryker in terms of upside potential today.
SYKNegative Net Change ISRGNegative Net Change
medical medical-devices
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
by Zacks Equity Research
Merit Medical shows resilience despite 2025 share pressure, supported by cardiovascular growth, margin expansion and WRAPSODY CIE momentum.
BSXPositive Net Change MASINegative Net Change MMSINegative Net Change CORNegative Net Change
medical medical-devices
3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run
by Indrajit Bandyopadhyay
Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.
BTCYPositive Net Change HIMSNegative Net Change PRVANegative Net Change
medical medical-devices
FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform
by Zacks Equity Research
Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.
OMCLPositive Net Change FLGTNegative Net Change SDGRNegative Net Change CCLDNegative Net Change
medical medical-devices
BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens
by Zacks Equity Research
BrainsWay stock rises after Optum expands Deep TMS coverage for adolescents, boosting reimbursement visibility.
BSXPositive Net Change ISRGNegative Net Change MEDPPositive Net Change BWAYNegative Net Change
medical medical-devices
Hims & Hers Expands Subscription-Led Care as Platform Engagement Grows
by Debanjana Dey
HIMS deepens its subscription-led model with new care verticals, diagnostics and global expansion to boost retention.
MEDPositive Net Change AMWLPositive Net Change HIMSNegative Net Change
medical medical-devices
The Zacks Analyst Blog Highlights Eli Lilly, Shell, ICICI Bank, Frequency Electronics and Vaso
by Zacks Equity Research
Eli Lilly anchors Zacks' latest Analyst Blog, with new research highlighting pharma growth drivers alongside global energy and banking insights.
LLYPositive Net Change IBNNegative Net Change FEIMPositive Net Change VASONegative Net Change SHELNegative Net Change
computers finance medical-devices oil-energy pharmaceuticals
The Zacks Analyst Blog Highlights Cardinal Health, Medtronic, Intuitive Surgical and Edwards Lifesciences
by Zacks Equity Research
Cardinal Health leads Zacks' list of large-cap MedTech stocks as AI adoption, robotics and rising procedure volumes set up continued gains in 2026.
MDTNegative Net Change ISRGNegative Net Change CAHPositive Net Change EWPositive Net Change
medical medical-devices
Should You Hold On To BSX Stock Despite Its Premium Valuation?
by Moumi Mondal
Boston Scientific trades at a premium, but strong momentum in WATCHMAN, EP and MedSurg growth keeps long-term shareholders in the game despite valuation risks.
ABTPositive Net Change BSXPositive Net Change MDTNegative Net Change
medical medical-devices
Top Analyst Reports for Eli Lilly, Shell & ICICI Bank
by Mark Vickery
LLY's strong GLP-1 demand, international launches and new drug contributions highlight why it leads today's top analyst reports lineup.
LLYPositive Net Change DBPositive Net Change IBNNegative Net Change GMPositive Net Change MKLNegative Net Change FEIMPositive Net Change VASONegative Net Change SHELNegative Net Change
computers finance medical-devices oil-energy pharmaceuticals
BD and Penn Institute Ink Collaboration to Advance Immunotherapy
by Zacks Equity Research
BDX teams up with the Penn Institute for Immunology and Immune Health to launch a high-parameter immune profiling study.
BDXPositive Net Change ISRGNegative Net Change CAHPositive Net Change COONegative Net Change
medical medical-devices
4 Large-Cap MedTech Stocks to Keep Winning Streaks Alive in 2026
by Harshit Gupta
Four large-cap MedTech leaders, MDT, ISRG, CAH, EW, appear well-positioned to extend their winning streaks in 2026 on resilient procedure demand and innovation.
MDTNegative Net Change ISRGNegative Net Change CAHPositive Net Change EWPositive Net Change
medical medical-devices
Cactus, Inc. (WHD)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
WHDNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
O-I Glass (OI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
OIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
EverQuote (EVER) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
EVERPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
HOLX vs. LH: Which MedTech Stock Is the Stronger Investment Now?
by Moumi Mondal
Labcorp's strategic partnerships, specialty test growth and more attractive valuation tilt the balance as it emerges stronger than Hologic right now.
LHPositive Net Change HOLXNegative Net Change
medical medical-devices
Here's Why You Should Retain INSP Stock in Your Portfolio Now
by Zacks Equity Research
INSP's Inspire V gains traction with strong clinical data, improving reimbursement visibility and cost control, even as inventory and GLP-1 headwinds persist.
MEDPPositive Net Change INSPPositive Net Change KRMDNegative Net Change CCLDNegative Net Change
medical medical-devices
Cencora to Acquire OneOncology to Expand Community Oncology Solutions
by Zacks Equity Research
COR's $3.6 billion move to take control of OneOncology boosts its pharma-centric strategy and lifts its long-term growth outlook despite a short-term dip.
MDPositive Net Change CORNegative Net Change BDSXPositive Net Change BTSGNegative Net Change
medical medical-devices